Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path
Amgen settled patent infringement litigation with AbbVie, allowing its Humira biosimilar Amjevita to launch in Europe in October 2018, but blocking entry in the US until 2023. The deal could set a bar for other Humira biosimilar developers.
You may also be interested in...
Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.